| Theme | Recent Advances in Diagnosis and Treatment of Reflux Esophagitis | |
|---|---|---|
| Title | Treatment of Reflux Esophagitis Using Acid Suppressants | |
| Publish Date | 2004/11 | |
| Author | Shuichi Ohara | Department of Gastroenterology, Tohoku University Hospital |
| Author | Masashi Kawamura | Department of Gastroenterology, Tohoku University Hospital |
| Author | Ken Ariizumi | Department of Gastroenterology, Tohoku University Hospital |
| Author | Tomoyuki Koike | Department of Gastroenterology, Tohoku University Hospital |
| Author | Akira Imatani | Department of Gastroenterology, Tohoku University Hospital |
| Author | Hitoshi Sekine | Department of Gastroenterology, Tohoku University Hospital |
| Author | Katsunori Iijima | Department of Gastroenterology, Tohoku University Hospital |
| Author | Tooru Shimosegawa | Department of Gastroenterology, Tohoku University Hospital |
| [ Summary ] | Reflux esophagitis is caused by abnormal acid reflux into the esophagus. Therefore, acid suppressants (PPIs and H2-recepter antagonists) are useful drugs for the treatment of this condition. PPIs, which suppress acid secretion to a greater degree and for a longer duration (24 hours) than H2-recepter antagonists, show higher and more effective healing rates. It has been reported that there were no obvious differences in the therapeutic effects of individual types of PPI for reflux esophagitis. However, it has recently, been shown that the acid inhibitory effects of PPIs depend on P450 2C19 (CYP2C19) polymorphism, and that the healing rates for reflux esophagitis using lansoprazole depended on the genotype CYP2C19. Therefore, one choice for therapy is to change the dosage or the type of PPI for incurable cases of reflux esophagitis. | |